On August 17 2023, CUREVAC N.V ($NASDAQ:CVAC) released their second quarter earnings report for the fiscal year 2023, ending June 30 2023. Total revenue for the quarter decreased by 62.4%, amounting to EUR 7.6 million, in comparison to the same period in the previous year. Net income for the quarter was EUR -67.4 million, a decrease from -57.6 million in the prior year.
The stock opened at $9.1 and closed the day at $8.6 – representing a 8.1% drop from the prior closing price of $9.4. Analysts have attributed the fall to concerns around the company’s long-term prospects. This has led to investors re-evaluating their positions and reducing their exposure to the company. CUREVAC N.V has yet to release a detailed explanation of its second quarter earnings, though it is expected to do so in the next few weeks. Investors will be watching closely to see if the company can turn its fortunes around, particularly in light of the uncertain economic environment. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Curevac N.v. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Curevac N.v. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Curevac N.v. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Curevac N.v are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale provides an analysis of CUREVAC N.V.’s fundamentals to help investors better understand this company. Our Star Chart shows that CUREVAC N.V has an intermediate health score of 6/10 with regard to its cashflows and debt, indicating that it might be able to safely ride out any crisis and not be at risk of bankruptcy. Additionally, CUREVAC N.V scores strongly in terms of its asset strength, growth potential, but is weak in dividend payments and profitability. We classify CUREVAC N.V as a ‘rhino’ company, meaning it has achieved moderate revenue or earnings growth. Given this analysis, investors who are looking for moderate growth in a company’s performance may find CUREVAC N.V an attractive prospect. Those who are looking for higher returns or more dividend payments may need to look elsewhere. Overall, GoodWhale provides a comprehensive analysis of CUREVAC N.V’s fundamentals to help investors make the best decision for their portfolio. More…
Risk Rating Analysis
Star Chart Analysis
The race to develop a coronavirus vaccine is heating up, with CureVac NV joining Moderna Inc, BioNTech SE, and Novavax Inc in the race to create a working vaccine. All four companies are racing to create a vaccine that can be used to protect people from the deadly virus. The competition between the companies is fierce, and each is hoping to be the first to develop a working vaccine.
Moderna Inc is a clinical stage biotechnology company that focuses on the discovery, development, and commercialization of therapeutics and vaccines based on messenger RNA (mRNA). As of 2022, Moderna has a market capitalization of $60.86 billion and a return on equity of 55.93%. The company’s mRNA platform has the potential to create medicines for a wide range of diseases and conditions, including cancer, infectious diseases, and rare genetic disorders. Moderna’s most advanced mRNA product candidates are in clinical trials for the treatment of COVID-19, influenza, and RSV.
As of 2022, BioNTech SE has a market cap of 37.45B and a Return on Equity of 63.88%. The company is a biotechnology company that develops and manufactures personalised vaccines against cancer and other infectious diseases.
Novavax Inc is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. The company has a market cap of 1.52B as of 2022 and a ROE of 507.51%. Novavax’s mission is to serve as a global leader in the development, manufacture and commercialization of innovative vaccines to prevent serious and life-threatening infectious diseases.
CUREVAC N.V recently reported their earnings results for the second quarter of fiscal year 2023, ending on June 30 2023. Total revenue for the quarter was EUR 7.6 million, a decrease of 62.4% from the same period last year. Net income was reported at EUR -67.4 million, compared to -57.6 million in the previous year.
This news caused the stock price to move down on the same day, indicating investors are not confident in the company’s future performance. It is important for investors to analyze the company’s revenue, expenses, and future prospects to determine if investing in CUREVAC N.V is a wise decision.